Who Still Needs Monotherapy in EGFR- Mutant NSCLC

Recording live at the 2026 World Conference on Lung Cancer in Seoul, South Korea, Estelamari Rodriguez, MD, MPH, from Sylvester Comprehensive Cancer Center, along with Misako Nagasaka, MD, PhD, from the University of California, Irvine School of Medicine, and Christine Lovly, MD, PhD, from City of Hope in Los Angeles, discuss first-lineEGFR-mutant NSCLC combinations, toxicity management, and PALOMA-2.